TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females and males, 18 years of older with overactive bladder symptoms~Exclusion Criteria:~* Treatable conditions that may cause urinary incontinence~* Medical conditions in which it would be unsafe to use an anti-cholinergic agent.~* The use of concomitant drugs that would confound the efficacy evaluation.~* The use of concomitant drugs that would be unsafe with an anti-cholinergic agent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oxybutynin topical gel (Type: EXPERIMENTAL): Oxybutynin topical gel
- Placebo topical gel (Type: PLACEBO_COMPARATOR): placebo topical gel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Currently receiving an ARV regimen of DTG+F/TAF or DTG+F/TDF for the following minimum time periods:~  * ≥ 6 months (if there is documented or suspected nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) resistance prior to the screening visit)~ * ≥ 3 months (if there is no documented or suspected NRTI resistance prior to the screening visit)~* Documented plasma HIV-1 ribonucleic acid (RNA) \< 50 copies/mL during treatment with DTG+F/TAF or DTG+F/TDF (for a minimum period of ≥ 6 or ≥ 3 months, as applicable) preceding the screening visit~* Plasma HIV-1 RNA levels \< 50 copies/mL at screening visit~* Estimated Glomerular Filtration Rate (eGFR) ≥ 30 mL/min according to the Cockcroft-Gault formula for creatinine clearance~* No documented resistance to integrase stand transfer inhibitors (INSTIs) or confirmed virologic failure~* Eligible adults with chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection are permitted to enroll~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B/F/TAF (Type: EXPERIMENTAL): Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) fixed-dose combination (FDC) tablet + dolutegravir (DTG) placebo tablet + emtricitabine/tenofovir alafenamide (F/TAF) placebo tablet administered without regard to food for at least 48 weeks.
- DTG + F/TAF (Type: ACTIVE_COMPARATOR): DTG 50 mg tablet + F/TAF FDC tablet + B/F/TAF placebo tablet administered without regard to food for at least 48 weeks.
- Open-label Phase B/F/TAF from B/F/TAF (Type: EXPERIMENTAL): Participants who received B/F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.
- Open-label Phase B/F/TAF from DTG + F/TAF (Type: EXPERIMENTAL): Participants who received DTG + F/TAF in double-blind phase and from a country where B/F/TAF was not available were given the option to receive B/F/TAF orally once daily for up to 96 weeks in the open-label extension phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Analgesic Modalities for Breast Cancer Surgeries

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* female 18-65 years old patients undergoing modified radical mastectomy~Exclusion Criteria:~* patient refusal, local infection at site of block coagulation defect abnormal kidney or liver functions

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- erector spinae block (Type: EXPERIMENTAL): Ultrasound guided erector spinae block with will be done after induction of intravenous anesthesia. After identification of trapezius, rhomboid major, and erector spinae muscles. The needle will be inserted in a cephalad-to-caudal direction until the tip contact transverse process and the needle tip is visualized in the plane deep to the erector spinae muscle. The needle tip position is confirmed by visualizing linear spread of test dose between the muscles after injection. A total dose of 25 mL of 0.25% bupivacaine will be injected.
- serratus anterior block (Type: EXPERIMENTAL): Ultrasound guided serratus anterior block will be done after induction of intravenous anesthesia. The serratus anterior, latissimus dorsi, and the intercostal muscles will be identified in the fourth and fifth intercostal level, an 18 G Tuohy needle will be advanced in the plane between the serratus anterior muscle and the intercostal muscles. A total dose of bupivacaine 25ml in a concentration of 0.25% will be administered under the serratus muscle after a test dose using an in-plane technique.
- intravenous morphine (Type: ACTIVE_COMPARATOR): intravenous morphine will be administrated in a dose of 0.1 mg per kg after induction of general anesthesia

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fluoxetine for Anxious Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~-~Patients must have:~Generalized anxiety disorder.~Exclusion Criteria:~-~Excluded:~Patients with current major depression, as well as patients with panic and obsessive-compulsive disorder.~-~Excluded:~Current substance abuse.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 17 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Medical history consistent with migraine with or without aura according to the International Headache Society (IHS) for at least 6 months prior to the study~* Between 3 to 12 migraine periods and no greater than 15 headache days (migraine and non-migraine) per month during the Baseline Phase~* No clinically significant abnormalities on neurological exams, electrocardiogram (ECG) or clinical laboratory test results at baseline~* Female patients must be postmenopausal for at least 1 year, surgically incapable of childbearing, practicing abstinence, or practicing an acceptable method of contraception (requires negative pregnancy test)~Exclusion Criteria:~* Patients with headaches other than migraine~* Patients with episodic tension or sinus headaches~* Onset of migraine after age of 50 years~* Patients who have failed more than two adequate regimens for migraine prophylaxis~* Patients who overuse pain medications or certain other medications

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to freely give written informed consent to participate in the study and have signed the Informed Consent Form;~2. Males or females, \>18 years of age inclusive at the time of study screening;~3. American Society of Anesthesiologists (ASA) Class I-III;~4. Infraperitoneal colorectal surgery (open and/or laparoscopic);~5. Elective Surgery~Exclusion Criteria:~1. Mentally incompetent or unable or unwilling to provide informed consent or comply with study procedures;~2. Children \<18;~3. No perioperative antibiotics;~4. Past or current urinary tract malignancy;~5. Urinary catheter inserted before surgery;~6. Chronic kidney insufficiency with Creatinine\> 2~7. Diagnosis of benign prostatic hyperplasia~8. Chronic urinary infections~9. Neurogenic bladder~10. History of enterovesical fistula~11. Pregnancy~12. Prior surgery of the lower urinary tract~13. Epidural~14. Perioperative ureteral stents~After randomization:~1. Catheter pulled out inadvertently;~2. Postoperative complications requiring prolonged monitoring of urine output~3. Postoperative complications requiring early reoperation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 24 hour postop catheter removal (Type: EXPERIMENTAL): group will receive the study medication prazosin ( 1 mg PO) 6 hours prior to catheter discontinuation (24 hours postoperatively)
- 72 hour postoperative catheter removal (Type: NO_INTERVENTION): catheter removed on postoperative day 3 (72 hours postoperatively)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female patients~* Age 18-65 years~* Eastern Cooperative Oncology Group (ECOG) status \< 2~* Surgery: R0-resection and \>= 10 removed axillary lymph nodes~* M0 by chest x-ray, bone scintigraphy and liver sonography~Exclusion Criteria:~* Polyneuropathy~* Creatinin (serum) \> 1,4 mg/dl; Bilirubin (serum) \> 2,0 mg/dl~* Cardia dysfunction, ejection fraction \< lower normal value of each institution~* Hematopoeitic insufficiency: leucocytes \< 3,5 G/l, thrombocytes \< 100 G/l~* second malignant neoplasia, except curatively treated basalioma of the skin~* Surgery before more the six weeks (42 days)~* Concurrent pregnancy; patients of childbearing potential must implement a highly effective (less than 1% failure rate) non-hormonal contraceptive measures during the study treatment~* Breast feeding woman~* Sequential breast cancer~* Reasons indicating risk of poor compliance~* Patients not able to consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- EC-Doc (Type: EXPERIMENTAL): 4 cycles epirubicin + docetaxel (90/600) i.v., q = 3 weeks, followed by 4 cycles docetaxel (100) i.v., q = 3 weeks
- CMF/CEF (Type: ACTIVE_COMPARATOR): 6 cycles cyclophosphamide, methotrexate, 5-fluorouracil (CMF) (600/40/600) i.v., day 1 + 8, q = 4 weeks or 6 cycles cyclophosphamide, epirubicin, 5-fluorouracil (CEF) (500/100/500) i.v., day 1, q = 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oral Androgens in Man-4: (Short Title: Oral T-4)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males between 18 to 55 years of age~* In good general health based on normal screening evaluation (consisting of a medical history, physical exam, normal serum chemistry, hematology, and baseline hormone levels)~* Subject must agree not to participate in another research drug study for the duration of the study~* Subject must agree to not donate blood during the study~* Subject must be willing to comply with the study protocol and procedures~Exclusion Criteria:~* Men in poor general health, with abnormal blood results (clinical laboratory tests or hormone values)~* A known history of alcohol or drug abuse~* A history of testicular disease or severe testicular trauma,~* A history of bleeding disorders or current use of anti-coagulants~* A history of sleep apnea and/or major psychiatric disorders~* A body-mass index greater than 35,~* A history of or current use of testosterone~* Infertility

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once
- 2 (Type: ACTIVE_COMPARATOR): Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female patients (21 to 65 yrs)~2. Diagnosis of Schizophrenia or Schizoaffective Disorder~3. Outpatients~4. On stable doses of atypical antipsychotics, either Olanzapine, Clozapine, or Risperidone for at least 1 month~5. Patients can be on other concomitant medications. Patients can be on antipsychotic polypharmacy, but there should not be more than 1 of the above 3 atypicals in a single prescription.~6. Patients should be able to provide written informed consent.~7. Currently with a BMI ≥ 25 (Overweight) and/or ≥7% increase in weight from pre-antipsychotic treatment.~Exclusion Criteria:~1. Previous allergy to Aripiprazole/contraindication to use of Aripiprazole~2. Participants with current substance misuse, including alcohol but excluding tobacco.~3. Non-compliant with prescribed medications~4. Mental Retardation~5. Presence of any major or unstable medical or neurological illness (such as uncontrolled diabetes and hypertension).~6. Participant with an eating disorder~7. Participants with serious suicidal thoughts, or who pose a serious risk of harm to self or to others.~8. Women who are pregnant or breastfeeding~9. Severe Personality Disorder~10. Diagnosis of Hyper or Hypothyroidism; Evidence of thyroid dysfunction as evidenced by serum thyroid function tests (i.e Thyroid Stimulating Hormone and Free Thyroxine (fT4) levels \> 10 % above or below the limits of the normal range~11. Use of any medication for weight loss within the past one month to the study entry~12. Clinically significant abnormalities in physical examinations, ECG or lab assessments~13. Baseline BMI \< 18.5kg/m2 (cut-off point for underweight adults as per World Health Organisation guidelines)~14. Unable to read or speak English

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Aripiprazole Adjunct (Type: EXPERIMENTAL): Aripiprazole 5 mg as a fixed dose as adjunct to other antipsychotics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with pulmonary emphysema due to severe congenital AAT deficiency of phenotype protease inhibitor Z (PiZ) or other rare genotypes (not MS, MZ or SZ) and AAT serum level \< 11 microns (µM) or \< 80 mg/dL (status to be confirmed by phenotyping and genotyping)~* Inspiratory capacity (VC - ERV) \> 1.2 L and forced expiratory volume at one second (FEV1) \< 80% of predicted value post bronchodilator~* FEV1/VC \< 70% of predicted value post-bronchodilator or transfer factor of carbon monoxide (KCO) \< 80% of predicted value post-bronchodilator~* History of at least one exacerbation in the past 2 years~* Written informed consent~Exclusion Criteria:~* FEV1 \< 25% of predicted value post-bronchodilator~* Augmentation therapy for more than one month with plasma-derived human alpha 1-antitrypsin (AAT) within the last 2 years~* History of lung transplant~* Any lung surgery within the past 2 years~* On any thoracic surgery waiting list~* Diagnosis of liver cirrhosis~* Severe concomitant disease~* Active pulmonary infection/exacerbations within the last month~* Active smoking during the last 6 months or plasma positive for cotinine~* Body weight \< 42 kg or \> 92 kg~* Pregnancy or lactation~* Women of child-bearing potential without adequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Prolastin
- Group 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Each patient must meet the following criteria to be enrolled in this study.~1. Is a child or an adolescent of 10 to \<18 years old, at Visit 1 (Screening)~2. Has been diagnosed with type 2 diabetes mellitus per American Diabetes Association diagnostic criteria~3. HbA1c of 6.5% to 11.0%, inclusive, in patients not taking insulin/SU, and of 6.5% to 12.0%, inclusive, in patients taking insulin/SU, at Visit 1 (Screening)~4. Has a C-peptide of \>0.6 ng/L at Visit 1 (Screening)~5. Has been treated with diet and exercise alone or in combination with a stable dose of an oral antidiabetic agent (e.g., metformin and/or SU) and/or insulin for their type 2 diabetes for at least 2 months prior to Visit 1 (Screening)~6. Has a fasting plasma glucose concentration \<280 mg/dL (15.5 mmol/L) at Visit 1 (Screening)~Patients who meet any of the following criteria will be excluded from the study.~1. Has a clinically significant medical condition that could potentially affect study participation and/or personal well-being, as judged by the Investigator, including but not limited to the following conditions:~   1. Hepatic disease (defined by aspartate or alanine transaminase \>3.0 times the upper limit of normal (ULN)~  2. Renal disease or serum creatinine \>1.5 mg/dL (132.6 µmol/L) (males) or 1.4 mg/dL (123.8 µmol/L) (females)~  3. Gastrointestinal disease deemed significant by the Investigator~  4. Organ transplantation~  5. Chronic infection (e.g., tuberculosis, human immunodeficiency virus, hepatitis B virus, or hepatitis C virus)~  6. Clinically significant malignant disease (with the exception of basal and squamous cell carcinoma of the skin) within 5 years of Visit 1 (Screening)~2. Has positive antibody titers to glutamic acid decarboxylase (GAD65) or islet cell antigen (ICA512) at Visit 1 (Screening)~3. Has a personal or family history of elevated calcitonin, calcitonin \>100 ng/L, medullary thyroid carcinoma, or multiple endocrine neoplasia-2~4. Has ever used exenatide (exenatide once weekly \[exenatide LAR\], exenatide BID, BYETTA, or any other formulation) or any glucagon-like peptide-1 (GLP-1) receptor agonist (e.g., liraglutide \[Victoza®\])~5. Is pregnant

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- EQW (Type: EXPERIMENTAL): Exenatide once weekly
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* History of a confirmed diagnosis of migraine headache with or without aura that meets the International Headache Society (IHS) criteria of migraine headache for at least 1 year~* Average frequency of 1 - 6 migraine headaches per month over the past 3 months~* History of migraine headaches of at least moderate pain intensity within the past year~* If taking a medication for migraine prophylaxis, taking a maintenance dose for at least 4 weeks prior to Visit 1, and remaining on a stable dose for the duration of the study~* In generally good health~* Capable of taking oral medication, perform study procedures and follow directions regarding collection of study information, e.g., subjects must be able and willing to read and comprehend written instructions, use a stopwatch, and comprehend and complete the telephone requirements, and must be willing to return to the office for a final study visit~* If female of childbearing potential, using birth control~Exclusion Criteria:~* Onset of migraine after age 50~* Chronic migraine or chronic tension-type headache defined by having 15 or more headache days per month in the previous 6 months~* Exclusively migraine aura without headache, or headaches that occur predominantly upon awakening in the morning~* Patients in whom triptans are contraindicated or who have previously discontinued AXERT therapy due to adverse events, history of substance abuse, or chronic alcohol abuse within the past 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete